New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype

Vaccine

Volumn 30, Issue 49, 2012, Pages 7078-7083

  Peeters, Ben ^a   Boer, Steffen Matthijn de ^b   Tjeerdsma, Gerjanne ^a   Moormann, Rob ^a   Koch, Guus ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

DIVA; H5N1; Influenza; Neuraminidase; Poultry; Vaccination

Indexed keywords

AVIAN INFLUENZA VACCINE; INACTIVATED VACCINE;

ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; CONTROLLED STUDY; DISCRIMINATING INFECTED FROM VACCINATED ANIMAL ASSAY; DRUG DETERMINATION; EMBRYO; HUMAN; HUMAN CELL; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; NONHUMAN; NUCLEOTIDE SEQUENCE; POULTRY; PRIORITY JOURNAL; SEROLOGY; VIRUS GENE; VIRUS RECOMBINANT; VIRUS SHEDDING;

ANIMALS; CHICKENS; CLOACA; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA IN BIRDS; INFLUENZA VACCINES; NEURAMINIDASE; RECOMBINANT FUSION PROTEINS; TRACHEA; VACCINES, INACTIVATED; VACCINES, MARKER; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84869080328     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.050     Document Type: Article

References (41)

1. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56(March (1)):152-179.
2. Alexander D.J. A review of avian influenza in different bird species. Vet Microbiol 2000, 74(May (1-2)):3-13.
3. Munster V.J., Fouchier R.A. Avian influenza virus: of virus and bird ecology. Vaccine 2009, 27(October (45)):6340-6344.
4. Bosch F.X., Garten W., Klenk H.D., Rott R. Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. Virology 1981, 113(September (2)):725-735.
5. Garten W., Bosch F.X., Linder D., Rott R., Klenk H.D. Proteolytic activation of the influenza virus hemagglutinin: the structure of the cleavage site and the enzymes involved in cleavage. Virology 1981, 115(December (2)):361-374.
6. Ohuchi M., Orlich M., Ohuchi R., Simpson B.E., Garten W., Klenk H.D., et al. Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). Virology 1989, 168(February (2)):274-280.
7. Horimoto T., Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994, 68(May (5)):3120-3128.
8. Shortridge K.F., Zhou N.N., Guan Y., Gao P., Ito T., Kawaoka Y., et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998, 252(December (2)):331-342.
9. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351(February (9101)):472-477.
10. Sims L.D., Ellis T.M., Liu K.K., Dyrting K., Wong H., Peiris M., et al. Avian influenza in Hong Kong 1997-2002. Avian Dis 2003, 47(3 (Suppl.)):832-838.
11. Olsen S.J., Ungchusak K., Sovann L., Uyeki T.M., Dowell S.F., Cox N.J., et al. Family clustering of avian influenza A (H5N1). Emerg Infect Dis 2005, 11(November (11)):1799-1801.
12. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008, 371(April (9622)):1427-1434.
13. van den Berg T., Lambrecht B., Marche S., Steensels M., Van Borm S., Bublot M. Influenza vaccines and vaccination strategies in birds. Comp Immunol Microbiol Infect Dis 2008, 31(March (2-3)):121-165.
14. van Oirschot J.T. Diva vaccines that reduce virus transmission. J Biotechnol 1999, 73(August (2-3)):195-205.
15. Capua I., Terregino C., Cattoli G., Mutinelli F., Rodriguez J.F. Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza. Avian Pathology 2003, 32(February (1)):47-55.
16. Lee C.W., Senne D.A., Suarez D.L. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza. Vaccine 2004, 22(August (23-24)):3175-3181.
17. Suarez D.L. Overview of avian influenza DIVA test strategies. Biologicals 2005, 33(December (4)):221-226.
18. Capua I., Alexander D.J. Avian influenza: recent developments. Avian Pathology 2004, 33(August (4)):393-404.
19. Wright P.F., Webster R.G. Orthomyxoviruses 2001, Lippincott Williams & Wilkins, Philadelphia. 4th ed.
20. Chen R., Holmes E.C. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008, 66(June (6)):655-663.
21. de Wit E., Bestebroer T.M., Spronken M.I., Rimmelzwaan G.F., Osterhaus A.D., Fouchier R.A. Rapid sequencing of the non-coding regions of influenza A virus. J Virol Methods 2007, 139(January (1)):85-89.
22. Hoffmann E., Stech J., Guan Y., Webster R.G., Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001, 146(December (12)):2275-2289.
23. Fodor E., Devenish L., Engelhardt O.G., Palese P., Brownlee G.G., Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999, 73(November (11)):9679-9682.
24. Peeters B.P., de Leeuw O.S., Koch G., Gielkens A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999, 73(June (6)):5001-5009.
25. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97(May (11)):6108-6113.
26. Office International des Epizooties. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals: Avian influenza; 2008.
27. Kapteyn J.C., Porre A.M., de Rond E.J., Hessels W.B., Tijms M.A., Kessen H., et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009, 27(February (9)):1468-1477.
28. de Boer G.F., Back W., Osterhaus A.D. An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol 1990, 115(1-2):47-61.
29. van der Goot J.A., van Boven M., Stegeman A., van de Water S.G., de Jong M.C., Koch G. Transmission of highly pathogenic avian influenza H5N1 virus in Pekin ducks is significantly reduced by a genetically distant H5N2 vaccine. Virology 2008, 382(December (1)):91-97.
30. Flandorfer A., Garcia-Sastre A., Basler C.F., Palese P. Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. J Virol 2003, 77(September (17)):9116-9123.
31. Nayak B., Kumar S., DiNapoli J.M., Paldurai A., Perez D.R., Collins P.L., et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 2010, 84(March (5)):2408-2420.
32. Ramp K., Veits J., Deckers D., Rudolf M., Grund C., Mettenleiter T.C., et al. Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens. Avian Dis 2011, 55(September (3)):413-421.
33. Van Deusen R.A., Hinshaw V.S., Senne D.A., Pellacani D. Micro neuraminidase-inhibition assay for classification of influenza A virus neuraminidases. Avian Dis 1983, 27(July-September (3)):745-750.
34. Avellaneda G., Sylte M.J., Lee C.W., Suarez D.L. A heterologous neuraminidase subtype strategy for the differentiation of infected and vaccinated animals (DIVA) for avian influenza virus using an alternative neuraminidase inhibition test. Avian Dis 2010, 54(March (1 Suppl.)):272-277.
35. Liu Y., Mundt E., Mundt A., Sylte M., Suarez D.L., Swayne D.E., et al. Development and evaluation of an avian influenza, neuraminidase subtype 1, indirect enzyme-linked immunosorbent assay for poultry using the differentiation of infected from vaccinated animals control strategy. Avian Dis 2010, 54(March (1 Suppl.)):613-621.
36. Moreno A., Brocchi E., Lelli D., Gamba D., Tranquillo M., Cordioli P. Monoclonal antibody based ELISA tests to detect antibodies against neuraminidase subtypes 1, 2 and 3 of avian influenza viruses in avian sera. Vaccine 2009, 27(August (36)):4967-4974.
37. Swayne D.E., Lee C.W., Spackman E. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathology 2006, 35(April (2)):141-146.
38. Bublot M., Le Gros F.X., Nieddu D., Pritchard N., Mickle T.R., Swayne D.E. Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand. Avian Dis 2007, 51(March (1 Suppl.)):332-337.
39. Cattoli G., Milani A., Temperton N., Zecchin B., Buratin A., Molesti E., et al. Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus. J Virol 2011, 85(September (17)):8718-8724.
40. Grund C., Abdelwhab el S.M., Arafa A.S., Ziller M., Hassan M.K., Aly M.M., et al. Highly pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-induced immunity but confers clinical protection against a heterologous clade 2.2.1 Egyptian isolate. Vaccine 2011, 29(July (33)):5567-5573.
41. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(August (8)):1596-1599.